Stratatech’s ExpressGraft begins human tests to treat diabetic foot ulcers
166873
post-template-default,single,single-post,postid-166873,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Stratatech’s ExpressGraft begins human tests to treat diabetic foot ulcers

Stratatech’s ExpressGraft begins human tests to treat diabetic foot ulcers

ExpressGraft-C9T1 is being used in first-round tests on a patient with diabetic foot ulcers — open sores that can affect patients with diabetes and can lead to amputation, said Mallinckrodt, the global pharmaceutical company whose Madison division, formerly Stratatech Corp., developed the tissue.

 

ExpressGraft-C9T1 is a genetically engineered, antimicrobial human skin substitute. It may benefit patients with “chronic, difficult-to-heal wounds such as those seen in patients with diabetes,” said Lynn Allen-Hoffmann, who was the founder and CEO of Stratatech and now is senior vice president of regenerative medicine at Mallinckrodt.

 

READ FULL STORY